Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.09
EPS est.
$-0.11
EPS surprise
+15.89%
1-day move
+0.60%
CytomX's earnings report shows a significant decline in revenue compared to last year, primarily due to the end of major collaborations. However, the stock reacted positively, increasing by 0.6%, likely due to the company's strong cash position and ongoing development of Varseta-M for colorectal cancer and other gastrointestinal cancers. Investors may be reassured by the projected cash runway into 2028.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | +15.89% |
| Revenue | $1.4M | N/A | N/A |
| Operating Expenses | $25.2M | N/A | +26.6% |
| Cash Equivalents | $330.3M | N/A | N/A |
Management expressed optimism about the company's cash position and ongoing development of Varseta-M. They highlighted the challenges faced due to the end of major collaborations.
CytomX has a strong cash runway projected into the second half of 2028.
Varseta-M is being developed for late-line colorectal cancer with plans for a registrational study in H1 2027.
CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $1 billion, it operates in the health care sector, emphasizing advancements in targeted therapies that aim to improve patient outcomes.
Last quarter
In Q1-2026, CytomX reported an EPS of -$0.10, outperforming estimates by 29.58%. However, the stock fell 3.15% the following day, indicating mixed investor sentiment.
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+14.52%
Avg 1-day reaction
+21.14%
Investors are cautiously optimistic about CytomX's upcoming earnings, given the company's recent performance and potential for surprises.
Bull case
If CytomX can demonstrate significant progress in its pipeline or report better-than-expected EPS, it could lead to a strong rally in the stock price.
Bear case
Conversely, if the company fails to meet expectations or provides disappointing guidance, it may face a sharp decline in its stock value.
The print will turn on these.
Q1
What is the projected EPS for this quarter?
EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment.
Q2
How is the pipeline progressing for key therapies?
Updates on the pipeline can indicate future revenue potential and overall company health, influencing stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±27.8%
Why consensus could be wrong
The Street may underestimate the impact of recent advancements in CytomX's pipeline, which could lead to better-than-expected results this quarter.
Supporting evidence
CytomX has a history of surprising on EPS, with a 63% beat rate over the last eight quarters.
The options market is pricing in a larger move than historical averages, indicating heightened expectations.
Recent performance trends suggest that the company may be on the verge of a breakthrough in its therapies.
Key risk
If the company can provide strong updates on its pipeline, it could significantly alter the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for earnings surprises against the backdrop of ongoing pipeline developments.
Bull confirmed if
A positive EPS surprise of $0.05 or more would confirm the bull case.
Bear confirmed if
An EPS loss greater than $0.15 would support the bear case.
What the market is pricing for the move.
Implied Move
±37.5%
Historical Avg
±22.9%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±37.5% while CTMX has averaged ±22.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
37.6%
Smart-money positioning from the most recent 13F filings.
Institutional
104.11%
of float
Insider
0.57%
of float
Holders
240
institutions
Top Holders· as of Jun 2026
FMR, LLC
32,714,937 sh · $83.4M
15.01%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CytomX beats expectations, history suggests a potential stock increase of around 25.2%, confirming investor confidence in the pipeline.
In line / cautious
An in-line report may lead to muted reactions, as investors await further guidance on future growth.
Miss
If the company misses expectations, history indicates a potential decline of about 15.16%, reflecting investor disappointment.
The lines on the call that would change the story.
Kynam Capital Management, LP
21,703,093 sh · $55.3M
9.96%
44.6%
Blackrock Inc.
17,559,822 sh · $44.8M
8.06%
235.9%
Bank of America Corporation
15,082,617 sh · $38.5M
6.92%
47.8%
State Street Corporation
11,747,236 sh · $30.0M
5.39%
107.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.